Early treatment of stage II sarcoidosis improves 5-year pulmonary function

Chest

Volumn 121, Issue 1, 2002, Pages 24-31

  Pietinalho, Anne ^a   Tukiainen, Pentti ^b   Haahtela, Tari ^b   Persson, Tore ^c   Selroos, Olof ^c  

^a Meltola Hospital   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensin converting enzyme; Budesonide; Chest radiograph; Glucocorticosteroids; Inhalation; Lung function; Prednisolone; Prognosis; Sarcoidosis

Indexed keywords

BUDESONIDE; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; PREDNISOLONE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FINLAND; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; THORAX RADIOGRAPHY; TREATMENT OUTCOME; URINE LEVEL;

EID: 0036157695     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.1.24     Document Type: Article

References (25)

1. ATS/ERS/ WASOG statement on sarcoidosis
2. Outcome of the treatment for sarcoidosis
3. Outcome in sarcoidosis: The relationship of relapse to corticosteroid therapy
4. Are corticosteroids harmful to sarcoidosis?
5. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: A double- blind, placebo-controlled multicenter study
6. Efficacy and safety of inhaled corticosteroids in asthma
7. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis
8. Pulmonary sarcoidosis and corticosteroids
9. Suppression of the alveolitis in pulmonary sarcoidosis by oral corticosteroids
10. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis
11. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis
12. A ten-year study of corticosteroid treatment of pulmonary sarcoidosis
13. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis
14. Corticosteroid therapy of pulmonary sarcoidosis: A prospective evaluation of alternate day and daily dosage in stage II disease
15. Pulmonary sarcoidosis: Long-term follow-up of the effects of steroid therapy
16. The present status of treatment of pulmonary sarcoidosis: A house divided
17. Corticosteroid therapy in sarcoidosis: A five-year, controlled follow-up study
18. British Thoracic Society sarcoidosis study: Effects of long term corticosteroid treatment
19. Evidence that steroids alter the natural history of previously untreated progressive pulmonary sarcoidosis
20. Effects of 18-month corticosteroid therapy on stage I and stage II sarcoid-osis patients (a control trial)
21. Clinical and functional results of a controlled clinical trial of the value of prednisolone therapy in sarcoidosis, stage I and II
22. Glucocorticoid receptors and actions
23. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis
24. γ-Interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis
25. Corticosteroid therapy suppresses spontaneous interleukin-2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis